Johnson and Johnson
May 18, 2017
Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J’s Invokana
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before they’ll really be able to celebrate. The U.S. Patent and Trademark Office’s Patent Trial and Appea...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
